Back to Search
RONALD DEMASI, M.D.
M.D.
Specialist
NPI: 1528139086IndividualAccepts Medicare
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
ME0066068(FL)
CMS Specialties
PrimaryGASTROENTEROLOGY
Education
BRODY SCHOOL OF MEDICINE AT EAST CAROLINA UNIVERSITY
Class of 1992
Research & Publications (20)
Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.
PMID 19202459·J Acquir Immune Defic Syndr·2008
2-rct
Adherence to enfuvirtide and its impact on treatment efficacy.
PMID 18240965·AIDS Res Hum Retroviruses·2008
4-observational
Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249.
PMID 18184079·AIDS Res Hum Retroviruses·2007
4-observational
Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.
PMID 18025893·AIDS·2007
3-trial
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
PMID 17711378·AIDS Patient Care STDS·2007
3-trial
Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
PMID 17563127·Clin Drug Investig·2007
4-observational
Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective.
PMID 17147497·AIDS Res Hum Retroviruses·2006
8-other
Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.
PMID 17125431·Pharmacotherapy·2006
4-observational
An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
PMID 17053351·AIDS·2006
6-review
Measurement of deeply virtual compton scattering with a polarized-proton target.
PMID 17026221·Phys Rev Lett·2006
8-other
HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.
PMID 16779731·J Infect Dis·2006
3-trial
Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
PMID 16765082·J Clin Virol·2006
3-trial
Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.
PMID 16706613·AIDS Res Hum Retroviruses·2006
3-trial
Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery.
PMID 16616230·J Vasc Surg·2006
3-trial
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
PMID 16280695·J Acquir Immune Defic Syndr·2005
3-trial
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
PMID 16280694·J Acquir Immune Defic Syndr·2005
3-trial
Discordant conclusions from HIV clinical trials--an evaluation of efficacy endpoints.
PMID 15918328·Antivir Ther·2005
8-other
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
PMID 15747252·J Infect Dis·2005
3-trial
Is three-dimensional computed tomography reconstruction justified before endovascular aortic aneurysm repair?
PMID 15337871·J Vasc Surg·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1370 E VENICE AVE, SUITE 210
VENICE, FL 34285 - Phone
- (941) 584-6272
Quick Facts
- NPI
- 1528139086
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile